135 related articles for article (PubMed ID: 19785071)
1. Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
Halldén G
J BUON; 2009 Sep; 14 Suppl 1():S61-7. PubMed ID: 19785071
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
Leitner S; Sweeney K; Oberg D; Davies D; Miranda E; Lemoine NR; Halldén G
Clin Cancer Res; 2009 Mar; 15(5):1730-40. PubMed ID: 19223497
[TBL] [Abstract][Full Text] [Related]
3. Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers.
Oberg D; Yanover E; Adam V; Sweeney K; Costas C; Lemoine NR; Halldén G
Clin Cancer Res; 2010 Jan; 16(2):541-53. PubMed ID: 20068104
[TBL] [Abstract][Full Text] [Related]
4. The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models.
Cherubini G; Kallin C; Mozetic A; Hammaren-Busch K; Müller H; Lemoine NR; Halldén G
Gene Ther; 2011 Dec; 18(12):1157-65. PubMed ID: 21975464
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region.
Miranda E; Maya Pineda H; Öberg D; Cherubini G; Garate Z; Lemoine NR; Halldén G
PLoS One; 2012; 7(10):e46617. PubMed ID: 23056370
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
Radhakrishnan S; Miranda E; Ekblad M; Holford A; Pizarro MT; Lemoine NR; Halldén G
Hum Gene Ther; 2010 Oct; 21(10):1311-25. PubMed ID: 20497039
[TBL] [Abstract][Full Text] [Related]
7. An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
Bhattacharyya M; Francis J; Eddouadi A; Lemoine NR; Halldén G
Cancer Gene Ther; 2011 Oct; 18(10):734-43. PubMed ID: 21836633
[TBL] [Abstract][Full Text] [Related]
8. Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdΔΔ and Dietary Phytochemicals in Prostate Cancer Models.
Adam V; Ekblad M; Sweeney K; Müller H; Busch KH; Johnsen CT; Kang NR; Lemoine NR; Halldén G
Hum Gene Ther; 2012 Sep; 23(9):1003-15. PubMed ID: 22788991
[TBL] [Abstract][Full Text] [Related]
9. Advances in oncolytic adenovirus therapy for pancreatic cancer.
Nattress CB; Halldén G
Cancer Lett; 2018 Oct; 434():56-69. PubMed ID: 29981812
[TBL] [Abstract][Full Text] [Related]
10. 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer.
Eisenberg DP; Adusumilli PS; Hendershott KJ; Yu Z; Mullerad M; Chan MK; Chou TC; Fong Y
J Gastrointest Surg; 2005 Nov; 9(8):1068-77; discussion 1077-9. PubMed ID: 16269377
[TBL] [Abstract][Full Text] [Related]
11. The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells.
Man YKS; Davies JA; Coughlan L; Pantelidou C; Blázquez-Moreno A; Marshall JF; Parker AL; Halldén G
Mol Cancer Ther; 2018 Feb; 17(2):575-587. PubMed ID: 29367266
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel increases antitumor efficacy of oncolytic prostate-restricted replicative adenovirus by enhancing cell killing and virus distribution.
Li X; Liu Y; Tang Y; Roger P; Jeng MH; Kao C
J Gene Med; 2010 Jun; 12(6):516-27. PubMed ID: 20527044
[TBL] [Abstract][Full Text] [Related]
13. 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells.
Halloran CM; Ghaneh P; Shore S; Greenhalf W; Zumstein L; Wilson D; Neoptolemos JP; Costello E
J Gene Med; 2004 May; 6(5):514-25. PubMed ID: 15133762
[TBL] [Abstract][Full Text] [Related]
14. A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel.
Mato-Berciano A; Raimondi G; Maliandi MV; Alemany R; Montoliu L; Fillat C
Oncotarget; 2017 Apr; 8(14):22700-22715. PubMed ID: 28186974
[TBL] [Abstract][Full Text] [Related]
15. The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11.
Pantelidou C; Cherubini G; Lemoine NR; Halldén G
Oncotarget; 2016 Mar; 7(13):15703-24. PubMed ID: 26872382
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
Heinemann L; Simpson GR; Boxall A; Kottke T; Relph KL; Vile R; Melcher A; Prestwich R; Harrington KJ; Morgan R; Pandha HS
BMC Cancer; 2011 Jun; 11():221. PubMed ID: 21645351
[TBL] [Abstract][Full Text] [Related]
17. AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.
Maliandi MV; Mato-Berciano A; Sobrevals L; Roué G; José A; Fillat C
Mol Cancer; 2015 Jul; 14():146. PubMed ID: 26227809
[TBL] [Abstract][Full Text] [Related]
18. Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer.
Onimaru M; Ohuchida K; Nagai E; Mizumoto K; Egami T; Cui L; Sato N; Uchino J; Takayama K; Hashizume M; Tanaka M
Cancer Lett; 2010 Aug; 294(2):178-86. PubMed ID: 20163915
[TBL] [Abstract][Full Text] [Related]
19. Complexing the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T with Cationic Nanoparticles Enhances Viral Infection and Spread in Prostate and Pancreatic Cancer Models.
Man YKS; Aguirre-Hernandez C; Fernandez A; Martin-Duque P; González-Pastor R; Halldén G
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012152
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.
Halldén G; Portella G
Expert Opin Ther Targets; 2012 Oct; 16(10):945-58. PubMed ID: 22880939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
